Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Eli Lilly and Company
LY-503430
Другие языки:

    LY-503430

    Подписчиков: 0, рейтинг: 0
    LY-503430
    LY503430.svg
    Clinical data
    Other names LY-503430; (R)-4'-[1-fluoro-1-methyl-2-(propane-2-sulfonylamino)-ethyl]-biphenyl-4-carboxylic acid methylamide
    Routes of
    administration    		 Oral
    Legal status
    Legal status
    Identifiers
    • 4'-{(1S)-1-fluoro-2-[(isopropylsulfonyl)amino]-1-methylethyl}-N-methylbiphenyl-4-carboxamide
    CAS Number
    PubChem CID
    ChemSpider
    UNII
    Chemical and physical data
    Formula C20H25FN2O3S
    Molar mass 392.49 g·mol−1
    3D model (JSmol)
    • CC(C)S(=O)(=O)NCC(F)(C)c(cc2)ccc2-c(cc1)ccc1C(=O)NC
    • InChI=1S/C20H25FN2O3S/c1-14(2)27(25,26)23-13-20(3,21)18-11-9-16(10-12-18)15-5-7-17(8-6-15)19(24)22-4/h5-12,14,23H,13H2,1-4H3,(H,22,24)/t20-/m0/s1 ☒N
    • Key:MFJKNXILEXBWNQ-FQEVSTJZSA-N ☒N
     ☒NcheckY (what is this?)  (verify)

    LY-503430 is an AMPA receptor positive allosteric modulator developed by Eli Lilly.

    LY-503430 produces both nootropic and neuroprotective effects, reducing brain damage caused by 6-hydroxydopamine or MPTP and also increasing levels of the neurotrophic factor BDNF in the brain, particularly in the substantia nigra, hippocampus, and striatum. It is orally active and the main application it is currently being developed for is treatment of Parkinson's disease, although it has also been proposed to be useful in the treatment of Alzheimer's disease, depression, and schizophrenia.

    See also



    Новое сообщение